NCT02789254已完成1 期
First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 10
- 主要终点
- Incidence and severity of adverse events (AE) (CTCAE V 4.03)
研究概览
简要总结
This is a first in human, prospective, multicentric, nonrandomized, open-label study to investigate the safety, tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of the Fc-optimized antibody FLYSYN as monotherapy in adult subjects.
详细描述
Cohort 1:
Patient 1-3: FLYSYN 0.5 mg/m² body surface area (BSA) day 1
Cohort 2:
Patient 4-6: FLYSYN 0.5 mg/m² body surface area (BSA) day 1 FLYSYN 1.0 mg/m² BSA day 2
Cohort 3:
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years at the time of voluntarily signing an IEC-approved informed consent, there is no upper age limit
- •Diagnosis of AML according to WHO criteria
- •Confirmed FLT3 expression on leukemic cells
- •Known mutational status of FLT3 (FLT3-ITD, FLT3-TKD, FLT3 wild type)
- •Hematological CR (ANC count >1.000/μL, Thrombocytes > 100.000/μL), but MRD positivity (determined by NGS and NPM1 RT-PCR, where applicable) after any therapy except allogeneic stem cell transplantation
- •Life expectancy of > 3 months
- •ECOG performance status ≤ 2
- •Subject must be willing to receive transfusion of blood products
- •Be willing and able to comply with the study protocol for the duration of the study
- •Females of childbearing potential (FCBP) must undergo repetitive pregnancy testing (serum or urine) and results must be negative
- •Reliable contraception should be maintained throughout the study and for 6 months after study treatment
- •Unless practicing complete abstinence from heterosexual intercourse, sexually active FCBP must agree to use adequate contraceptive methods
- •Males (including those who have had a vasectomy) must use an effective barrier method of contraception throughout the study and for 6 months after study treatment if sexually active with a female of childbearing potential
- •All subjects must:
- •understand that the investigational product could have a potential teratogenic risk.
- •be counseled about pregnancy precautions and risks of fetal exposure.
- •be able to comply with all study-related procedures, medication use, and evaluations.
排除标准
- •The presence of ANY of the following criteria will exclude a patient from study enrollment:
- •Patients proceeding to hematopoietic stem cell transplantation (suitable candidate and donor available, informed consent of patient)
- •Pregnant or breast feeding females
- •>5% blasts in bone marrow or extramedullary disease
- •Treatment with monoclonal antibody within 3 months before treatment with FLYSYN or known immunoglobulin intolerance
- •Known positivity for HIV, active HBV, HCV, or Hepatitis A infection
- •No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment about study participation
- •No consent for biobanking
- •Presence of any medical/psychiatric condition or laboratory abnormalities which may limit full compliance with the study, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- •Prior history of malignancies, other than AML/MDS, unless the subject has been free of the disease for ≥ 2 years. Exceptions include the following: Basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, histological finding of prostate cancer of TNM stage T1
- •Patients receiving any medication listed in the Appendix IV "Prohibited Medications" (within 14 days prior to the first dose of study drug)
- •Uncontrolled infection, e.g. infection progressing under adequate antimicrobial/antifungal/antiviral treatment
- •Patients under ongoing treatment with another investigational medication or having been treated with an investigational medication within 14 days of screening
- •Current treatment with immunosuppressive agents
- •Systemic diseases (cardiovascular, renal, hepatic, etc.) that would prevent study treatment (e.g., creatinine >1.5x upper normal serum level; bilirubin, AST or AP >2.5x upper normal serum level; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
结局指标
主要结局
Incidence and severity of adverse events (AE) (CTCAE V 4.03)
时间窗: until 28 days (i.e. Visit7, day 29) after last dosing
次要结局
- Change in cytokines from baseline(Visits 1-3;5 +6)
- Pharmacokinetics and pharmacodynamics(Visit 1 to 13)
- Immunogenicity of FLYSYN based on both absolute (number and percentage of subjects who develop HAMA/HAHA) and semi-quantitative (HAMA/HAHA titer determination of confirmed positive samples) assessments(BSL; Visits 5-7;9-13)
- Incidence and severity of adverse events (AE) (CTCAE V 4.03)(until 180 days (i.e.Visit 11, day 180) after last dosing)
- Duration of response, time to MRD progression (log step), time to relapse(BSL; Visits1;4-13)
- Absolute and percent change from baseline in measurements of B, T, and NK cell populations and activation(Visits 1;3;4;5;9)
- Overall response rate, defined as MRD negativity or reduction of at least one log step,(BSL; Visits1;4-13)
- Absolute change from baseline in overall quality of life scores (EORTC QLQ C-30)(Visit 1, Visit 6,Visit 9,Visit 10, Visit 11, Visit 12, Visit 13)
研究者
研究点 (10)
Loading locations...
相似试验
招募中
1 期
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMHypertrophic CardiomyopathyNCT05836259Tenaya Therapeutics30
招募中
不适用
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery DiseaseSuperficial Femoral Artery StenosisPopliteal Artery StenosisNCT06410313Medinol Ltd.30
已完成
1 期
A First-in-Human Study of CEE321 in Adult SubjectsAtopic DermatitisNCT04612062Novartis Pharmaceuticals28
已完成
1 期
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsAdvanced Solid TumorNCT04896697Xilio Development, Inc.125
撤回
1 期
Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid TumorsPancreas CancerSolid TumorGastric CancerNCT05181865Flame Biosciences